ACAndrew Kean Wei Chang

Andrew Kean Wei Chang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew Kean Wei Chang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Hock Hin Chua

    Infectious Disease Unit, Medical Department, Sarawak General Hospital, Jalan Hospital, 93586, Kuching, Sarawak, Malaysia

    2 shared publications
  • Jeremy Wrobel

    Advanced Lung Disease and Lung Transplantation Unit, Fiona Stanley Hospital, Perth, Australia

    2 shared publications
  • Melanie Lavender

    Advanced Lung Disease and Lung Transplantation Unit, Fiona Stanley Hospital, Perth, Australia

    2 shared publications
  • Meow‐Chong Yaw

    Advanced Lung Disease and Lung Transplantation Unit, Fiona Stanley Hospital, Perth, Australia

    2 shared publications
  • Michael Musk

    Advanced Lung Disease and Lung Transplantation Unit, Fiona Stanley Hospital, Perth, Australia

    2 shared publications
  • Peter Boan

    Department of Infectious Diseases Fiona Stanley Hospital Perth Western Australia Australia

    2 shared publications

Latest Publications

  • Open Access

    Primary traumatic cutaneous aspergillosis of the hand caused by Aspergillus terreus following a mould-contaminated penetrating injury

    by Shan Kai Ing, Yih Hoong Lee, Yuet Yang Tan, Munirah Binti Abdul Aziz, Andrew Kean Wei Chang


  • Open Access

    Pulmonary tuberculosis and COVID-19 coinfection: Hickam's Dictum revisited

    by Larry Ellee Nyanti, Zhun Han Wong, Benjamin Sachdev Manjit Singh, Andrew Kean Wei Chang, Ahmad Tirmizi Jobli, Hock Hin Chua


  • Open Access

    Miscarriage Risk in COVID-19 Infection

    by Tze Cheng Wong, Zhi Yuan Lee, Tonnii L. L. Sia, Andrew K. W. Chang, Hock Hin Chua


  • Epidemiology of invasive fungal infections in lung transplant recipients in Western Australia

    by Andrew Chang, Michael Musk, Melanie Lavender, Jeremy Wrobel, Meow‐Chong Yaw, Sharon Lawrence, Shiji Chirayath, Peter Boan

    Background: Invasive fungal infections (IFI) are common after lung transplantation with reported incidence of 8.1% to 16% at 12 months post‐transplant, and 3‐month all‐cause mortality after IFI of 21.7%.Methods: We performed a retrospective study of IFI and fungal colonization in lung transplants (LTs) from November 2004 to February 2017.Results: 137 LTs were followed for a median 4.1 years (IQR 2.1‐6.2 years). In addition to nebulized amphotericin for the transplant admission to all LTs, systemic mold‐active azole was given to 80/130 (61.5%) LTs in the first 6 months post‐transplant, 57/121 (47.1%) in the period 6‐12 months after transplant, and 93/124 (75%) in the period more than 12 months post‐transplant. Mold airways colonization was found in 81 (59.1%) LTs before and 110 (80.3%) LTs after transplantation. There were 13 IFIs for an overall incidence of 2.1 per 100 person‐years, occurring at a median 583 days (IQR 182‐1110 days) post‐transplant, a cumulative incidence of 3.8% at 1 year, 7.6% at 3 years and 10.1% at 5 years post‐transplant. All‐cause 3‐month mortality after IFI was 7.7%. Aspergillus species followed by Scedosporium apiospermum and Cryptococcus species were the commonest fungi causing IFI.Conclusions: In our cohort the rate of IFI was comparatively low, likely because of comprehensive early antifungal use and preemptive therapy at any time after transplant. Prospective studies of fungal colonization late after LT are required to determine the risks and benefits of watchful waiting compared to preemptive therapy.


  • Cytomegalovirus viremia in lung transplantation during and after prophylaxis

    by Andrew Chang, Michael Musk, Melanie Lavender, Jeremy Wrobel, Meow‐Chong Yaw, Sharon Lawrence, Shiji Chirayath, Peter Boan

    Background: Lung transplantation has a high risk of cytomegalovirus (CMV) viremia and disease.Methods: Valganciclovir was planned for 6 months in CMV recipient seropositive (R+) lung transplants (LTs) and given long‐term in D+R− LTs. CMV viremia was monitored regularly during and after prophylaxis in all patients.Results: Of 137 LTs, 22 were D+R−, 49 D+R+, 43 D−R+, and 23 D−R−, with median follow up 4.1 years (IQR 2.1‐6.2 years). CMV viremia at any time occurred in 44.5% of LTs. CMV viral load >103 c/mL was uncommon (9/77 episodes). CMV viremia occurred at median 665 days (IQR 271‐1411 days), in 5.1% LTs 12 months. CMV disease occurred in 6 (4.4%) LTs at an overall rate of 1.0 episode per 100 person‐years: two of these cases were organ‐specific disease, four were CMV syndrome. One case of ganciclovir‐resistant CMV was diagnosed. D+R+ and D+R− LTs had higher viremia rates than the D−R+ group. No viremia occurred in D−R− LTs. CMV viremia was not associated with age, gender, type of LT, indication for LT, acute rejection, bronchiolitis obliterans syndrome, or mortality.Conclusions: Prophylaxis for 6 months in D+R+ and D−R+, and past 12 months in D+R− LTs, with long‐term monitoring in all patients using a sensitive assay, and reinstitution of valganciclovir for low‐level viremia was effective at markedly reducing the incidence of CMV disease. CMV D−R− LTs do not need routine CMV monitoring.